Dr. Tice is internationally recognized for his research and product development of complex parenteral, drug delivery dosage forms based on bioabsorbable polymer excipients. He is known for his accomplishments involving injectable, extended-release microparticles made with bioabsorbable lactide/glycolide polymers designed for systemic and local drug delivery. He was a team leader and core inventor to develop the first commercial, injectable, extended-release microparticle product. This product, a one-month LHRH formulation indicated for the treatment of prostate cancer (Decapeptyl® SR), is still on the market today. He has also served on various US Pharmacopeia expert committees for 15 years, and is currently on the General Chapters-Dosage Forms Expert Committee and Excipient Joint Committee.
At Evonik, Dr. Tice, provides scientific support to Evonik’s innovation, sales, product development, research, intellectual property and M&A teams.
He earned his BSc in Chemistry and PhD in Biophysics from Syracuse University, New York. He held a postdoctoral fellow position at the University of Alabama at Birmingham (UAB) in Microbiology. He holds 48 US patents with many foreign equivalents and has more than 180 publications, presentations and invited lectures to his credit. He flew experiments on two Space Shuttle flights.